Rivaroxaban treatment among children with cancer-associated thromboembolism: Real-world data.
cancer
pediatric
rivaroxaban
thrombosis
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
22
06
2022
received:
26
05
2022
accepted:
26
06
2022
pubmed:
21
7
2022
medline:
30
8
2022
entrez:
20
7
2022
Statut:
ppublish
Résumé
This is the first study examining real-life data of pediatric cancer patients treated with rivaroxaban. Children with thrombocytopenia and high bleeding risk were excluded from previous clinical trials. Data regarding the safety and efficacy of rivaroxaban in pediatric cancer-associated thrombosis are scarce. Our case series included 16 children aged 7.5-17 years. Thrombus resolution rate in our study was comparable to results of previous studies. However, higher rates of thrombotic and bleeding complications were seen in our study as compared to previous reports, especially among patients with relapsed or refractory disease.
Substances chimiques
Anticoagulants
0
Factor Xa Inhibitors
0
Rivaroxaban
9NDF7JZ4M3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29888Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5:927-974.
Costa OS, Kohn CG, Kuderer NM, Lyman GH, Bunz TJ, Coleman CI. Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. Blood Adv. 2020;4:4045-4051.
Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomized, controlled, phase 3 trial. Lancet Haematol. 2020;7:e18-e27.
Jaffray J, Young G. Direct oral anticoagulants for use in paediatrics. Lancet Child Adolesc Health. 2022;6:207-214.
Barg AA, Kenet G. Cancer-associated thrombosis in pediatric patients. Thromb Res. 2020;191(Suppl 1):S22-S25.
Thom K, Lensing AWA, Nurmeev I, et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Adv. 2020;4:4632-4639.
Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013;51:549-561.
Gaynor EP, Sullivan PB. Nutritional status and nutritional management in children with cancer. Arch Dis Child. 2015;100:1169-1172.
Douxfils J, Adcock DM, Bates SM, et al. 2021 Update of the international council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121:1008-1020.
Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020;18:1672-1685.